One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence.
Adult
Aged
Aged, 80 and over
Electric Stimulation Therapy
/ adverse effects
Electrodes, Implanted
/ adverse effects
Fecal Incontinence
/ complications
Female
Follow-Up Studies
Humans
Lumbosacral Plexus
/ surgery
Male
Middle Aged
Patient Satisfaction
Prostheses and Implants
Quality of Life
Surveys and Questionnaires
Treatment Outcome
Urinary Incontinence, Urge
/ psychology
Urinary Retention
/ complications
Urologic Surgical Procedures
/ methods
Young Adult
clinical trial
implantable neurostimulator
overactive bladder
sacral neuromodulation
urinary urgency incontinence
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
22
01
2020
accepted:
15
04
2020
pubmed:
28
4
2020
medline:
21
11
2020
entrez:
28
4
2020
Statut:
ppublish
Résumé
Sacral neuromodulation (SNM) is a guideline-recommended treatment for voiding dysfunction including urgency, urge incontinence, and nonobstructive retention as well as fecal incontinence. The Axonics® System is a miniaturized, rechargeable SNM system designed to provide therapy for at least 15 years, which is expected to significantly reduce revision surgeries as it will not require replacement as frequently as the non-rechargeable SNM system. The ARTISAN-SNM study is a pivotal study designed to treat patients with urinary urgency incontinence (UUI). Clinical results at 1-year are presented. A total of 129 eligible UUI patients were treated. All participants were implanted with a quadripolar tined lead and neurostimulator in a single procedure. Efficacy data were collected using a 3-day bladder diary, a validated quality of life questionnaire (ICIQ-OABqol), and a participant satisfaction questionnaire. Therapy responders were defined as participants with ≥50% reduction in UUI episodes compared to baseline. Data were analyzed on all 129 participants. At 1 year, 89% of the participants were therapy responders. The average UUI episodes per day reduced from 5.6 ± 0.3 at baseline to 1.4 ± 0.2. Participants experienced an overall clinically meaningful improvement of 34 points on the ICIQ-OABqol questionnaire. All study participants (100%) were able to recharge their device at 1 year, and 96% of participants reported that the frequency and duration of recharging was acceptable. There were no serious device-related adverse events. The Axonics System is safe and effective at 1 year, with 89% of participants experiencing clinically and statistically significant improvements in UUI symptoms.
Identifiants
pubmed: 32339339
doi: 10.1002/nau.24376
pmc: PMC7384085
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1482-1488Subventions
Organisme : Axonics Modulation Technologies
Pays : International
Informations de copyright
© 2020 The Authors. Neurourology and Urodynamics Published by Wiley Periodicals, Inc.
Références
Neurourol Urodyn. 2017 Mar;36(3):727-733
pubmed: 27062384
Neurourol Urodyn. 2014 Jun;33(5):488-92
pubmed: 23737158
Neurourol Urodyn. 2018 Jun;37(5):1823-1848
pubmed: 29641846
Neurourol Urodyn. 2018 Feb;37(S2):S1-S8
pubmed: 29336078
Neuromodulation. 2014 Jul;17(5):425-30; discussion 430
pubmed: 24112630
Neuromodulation. 2012 May-Jun;15(3):214-7; discussion 217-8
pubmed: 22074455
BJU Int. 2019 May;123(5A):E7-E13
pubmed: 30537223
Neuromodulation. 2017 Dec;20(8):836-840
pubmed: 29024404
Br J Neurosurg. 2014 Oct;28(5):645-9
pubmed: 24559123
JAMA Intern Med. 2019 Jun 24;:
pubmed: 31233095
Neurourol Urodyn. 2020 Jun;39(5):1482-1488
pubmed: 32339339
Neurourol Urodyn. 2016 Feb;35(2):246-51
pubmed: 25546568
J Urol. 2020 Jan;203(1):185-192
pubmed: 31347955
Neuromodulation. 2017 Dec;20(8):816-824
pubmed: 28975677
Neurourol Urodyn. 2019 Aug;38(6):1595-1601
pubmed: 31044466
Eur Urol. 2014 Jan;65(1):79-95
pubmed: 24007713
BJU Int. 2011 Oct;108(7):1132-8
pubmed: 21231991
Neurourol Urodyn. 2019 Feb;38(2):689-695
pubmed: 30592526
Rheumatology (Oxford). 2017 Apr 1;56(4):581-588
pubmed: 28013205